Bookmark! (press Ctrl+D)

Humanigen (OTCQB: HGEN) CEO Cameron Durrant joined Steve Darling from Proactive in Vancouver to discuss the company that it is actively exploring clinical-stage strategies and partnerships to evaluate whether “lenzilumab”, the company‚Äôs proprietary monoclonal antibody, may reduce or prevent cytokine storm resulting from COVID-19 infection.

Durrant talked about cytokine storms and their relation to a virus like Corona.

source

LEAVE A REPLY

Please enter your comment!
Please enter your name here